Replies to post #251436 on Biotech Values

[DewDiligence]

VINC reverse-merges with (private) Oqory, Inc:

https://www.globenewswire.com/news-release/2024/12/27/3002352/0/en/Vincerx-Pharma-Enters-into-a-Binding-Term-Sheet-for-a-Strategic-Merger-with-Oqory-Inc.html

Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%.

…Oqory, Inc. is an innovator in the field of ADCs with expertise in advancing targeted cancer therapies. The Company’s pipeline includes multiple ADC programs, with two currently in clinical development and several next-generation ADCs in preclinical stages.

I've lost count of the number of biotech companies working on ADCs. It's a large number.